HomeCompareAGGR vs MRK

AGGR vs MRK: Dividend Comparison 2026

AGGR yields 19.59% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGGR wins by $40.5K in total portfolio value
10 years
AGGR
AGGR
● Live price
19.59%
Share price
$10.21
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.2K
Annual income
$6,447.93
Full AGGR calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — AGGR vs MRK

📍 AGGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGGRMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGGR + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGGR pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGGR
Annual income on $10K today (after 15% tax)
$1,665.03/yr
After 10yr DRIP, annual income (after tax)
$5,480.74/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, AGGR beats the other by $4,672.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGGR + MRK for your $10,000?

AGGR: 50%MRK: 50%
100% MRK50/50100% AGGR
Portfolio after 10yr
$51.0K
Annual income
$3,699.11/yr
Blended yield
7.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AGGR
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGGR buys
0
MRK buys
0
No recent congressional trades found for AGGR or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGGRMRK
Forward yield19.59%3.25%
Annual dividend / share$2.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$71.2K$30.7K
Annual income after 10y$6,447.93$950.29
Total dividends collected$40.0K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AGGR vs MRK ($10,000, DRIP)

YearAGGR PortfolioAGGR Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,659$1,958.86$11,192$351.54+$1.5KAGGR
2$15,862$2,317.48$12,524$392.70+$3.3KAGGR
3$19,687$2,713.98$14,015$438.65+$5.7KAGGR
4$24,213$3,147.95$15,682$489.96+$8.5KAGGR
5$29,526$3,618.39$17,547$547.23+$12.0KAGGR
6$35,717$4,123.75$19,632$611.16+$16.1KAGGR
7$42,879$4,662.01$21,963$682.53+$20.9KAGGR
8$51,111$5,230.72$24,571$762.18+$26.5KAGGR
9$60,516$5,827.06$27,486$851.08+$33.0KAGGR
10$71,200$6,447.93$30,745$950.29+$40.5KAGGR

AGGR vs MRK: Complete Analysis 2026

AGGRStock

Agile Growth Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire businesses in the technology industry, including infrastructure, and horizontal and vertical enterprise application software; healthcare IT; financial technology; robotics/automation; and education technology, as well as additional software and technology segments. Agile Growth Corp. was incorporated in 2021 and is based in Newton, Massachusetts.

Full AGGR Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this AGGR vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGGR vs SCHDAGGR vs JEPIAGGR vs OAGGR vs KOAGGR vs MAINAGGR vs JNJAGGR vs ABBVAGGR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.